Awardee: Or Kakhlon
Institution: Research Fund of the Hadassah Medical Organization
Award Amount: $165,000
Funding Period: February 1, 2023 - January 31, 2024
The new lysosomal activator GHF201 (144DG11) as a potential treatment for mucopolysaccharidosis I”
Previous
Previous
Utilizing the PS Gene Editing System to Encode a Blood‐Brain Barrier‐Penetrating IDUA as a Treatment for Murine Hurler Syndrome
Next
Next